Oral Iron Therapy for Heart Failure With Reduced Ejection Fraction

Impaired exercise capacity is a cardinal manifestation of heart failure (HF) that is closely related to reduced quality of life and poor outcomes. Therapeutic options beyond neurohormonal blockade to improve functional capacity and symptoms in HF are currently limited and must be pursued. Iron deficiency is associated with reduced functional capacity and poorer quality of life in HF. Here, a rationale for oral iron repletion in patients with HF and iron deficiency is provided with an overview of the study design for the Iron Repletion effects on Oxygen Uptake in Heart Failure (IRONOUT HF) trial, which aims to study the effect of oral iron repletion on functional capacity in patients with HF and reduced ejection fraction (HFrEF).